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1. Genotyping and Quality Control 
 
COGA 
 Participants from the Collaborative Study on the Genetics of Alcoholism (COGA) 1, 2 were identified 
through alcohol treatment programs at six U.S. sites and were invited to participate if they had a sufficiently large 
family (usually sibships > 3 with parents available) with two or more members in the COGA catchment area. The 
Institutional Review Boards at all sites approved this study and written consent was obtained from all participants. 
Genotyping of the COGA samples was conducted across different phases of data collection. European ancestry (EA) 
samples were genotyped at multiple sites, including: (1) Center for Inherited Disease Research using the Illumina 
HumanHap1M array 3; (2) Genome Technology Access Center at Washington University School of Medicine using 
the Illumina OmniExpress 4; and (3) Rutgers University using the Affymetrix Smokescreen array 5. All A/T and C/G 
SNPs were removed and a common set of ~47,000 SNPs were used to assess duplicate samples and revise the 
reported pedigree structure. Family structures were altered as needed, and SNP genotypes were tested for Mendelian 
inconsistencies 6 with the revised family structure. Genotype inconsistencies were set to missing.  Data were 
imputed to 1000 Genomes (Phase 3, version 5) using SHAPEIT 7 and then Minimac3 8. Samples were imputed 
separately due to different variant contents on each array. In addition, the two datasets genotyped on the 
Smokescreen genotyping array were also imputed separately, due to different processing pipelines used by the 
genotyping laboratory. Prior to imputation, variants with missing rates > 5%, MAF < 3% and HWE p values < 
0.0001 were excluded, resulting in a total of 26,124,746 variants. Principal components were computed from GWAS 
data using Eigenstrat 9 and 1000 Genome reference panel. Individual ancestry was assigned using the YRI, CEU, 
JPT and CHB populations to set reference points. Genotypic data are available via controlled access on the Database 





 Twins enrolled into Finntwin12 were born between 1983 and 1987, identified through Finland’s Central 
Population Registry (CPR). Ascertainment was exhaustive, and twins in all pairs with both twins alive, resident in 
Finland and enrolled in normal public schools, were invited to participate. The Helsinki University Central Hospital 
District’s Ethical Committee and Indiana University’s Institutional Review Board approved the FinnTwin12 study. 
Genotyping was conducted using the Human670-QuadCustom Illumina BeadChip at the Wellcome Trust Sanger 
Institute 10. Quality control steps included removing SNPs with minor allele frequency (MAF) <1%, genotyping 
success rate <95%, or Hardy–Weinberg equilibrium p < 1 × 10−6, and removing individuals with genotyping success 
rate <95%, a mismatch between phenotypic and genotypic gender, excess relatedness (outside of known families), 
and heterozygosity outliers. Genotypes were imputed to the 1,000 Genomes Phase 3 reference panel 11 reference 
panel using ShapeIT 12 for phasing and IMPUTE2 13 for imputation, resulting in 13,688,418 autosomal SNPs for 
analyses. Data are available through the Biobank of the National Institute for Health and Welfare in Finland. See 
Kaprio et al. 2019 for specifics on data access. 
 
 
Common HapMap3 SNPs across sample and GWAS 
 Total # of HapMap3 SNPs in PRS 
 COGA FT12 
RISK PC PRS 1,110,737 1,098,765 
GSCAN DPW PRS 1,110,910 1,099,480 





2. Problematic Alcohol use Meta Analysis 
 
 In order to maximize the predictive power for polygenic scores (PRS) for problematic alcohol use, we 
meta-analyzed summary statistics from two recent large scale GWAS of problematic alcohol use. The first GWAS 
was conducted using the problem subscale of the Alcohol Use Disorder Identification Test (AUDIT-P) on ~120k 
individuals in the UK Biobank. The AUDIT-P is made up of items 4-10 (1-3 reflect consumptions, or AUDIT-C) of 
the full AUDIT. Scores on individual items range from 0 to 4, resulting in an overall range of 0 to 28 for the 
AUDIT-P. Items include: 
 
1. How often during the last year have you found that you were unable to stop drinking once you had started?  
2. How often during the last year have you failed to do what was normally expected of you because of your 
drinking 
3. How often during the last year have you needed a first drink in the morning to get yourself going after a 
heavy drinking session?  
4. How often during the last year have you had a feeling of guilt or remorse after drinking?  
5. How often during the last year have you been unable to remember what happened the night before because 
you had been drinking? 
6. Have you or someone else been injured as the result of your drinking? 
7. Has a relative, friend, or a doctor or other health worker been concerned about your drinking or suggested 
you cut down?  
 
The second GWAS was the Psychiatric Genetics Consortium’s (PGC) GWAS of alcohol dependence (AD) in ~45K 
individuals (European ancestry results only). This GWAS focused on lifetime diagnosis (or meeting the criteria for 
lifetime diagnosis on a clinical interview) of AD. As both COGA and FT12 were included in the initial PGC 
GWAS, we recalculated summary statistics with each cohort removed. The resulting meta-analyses was a GWAS of 
problematic alcohol use in ~160K individuals. 
 We first estimate the SNP-based heritability (h2SNP) and genetic correlations (rg) between each of the 
GWAS (UKB AUDIT-P, PGC AD with COGA removed, and PGC AD with FT12 removed) using LD score 
regression 15. Table S1 provides the estimates for h2SNP and rg. Both of the  PGC AD GWAS were sufficiently 
correlated with UKB AUDIT-P to justify meta-analysis. 
 To combine the results from these two sets of PGC summary statistics with the UKB AUDIT-P GWAS, we 
utilized a sample size based meta-analysis in METAL 16. In addition to the quality control metrics in the original 
GWASs, we constrained to SNPS with a MAF > 0.01. Independent SNPs (r2 < 0.1 ) that met genome-wide 
significance (GWS) for each meta-analysis are presented in Table S2. For the NO COGA META, there were 13 
significant SNPs, all on chromosome 4. The significant SNPs for the NO FT12 META were also on chromosome 4, 
however there was one additional independent SNP. In addition to these top SNPs, the Manhattan plots and QQ 
plots are available in Figures S1 and S2. 
 Follow up with the meta-analyzed results in LDSC revealed significant h2SNP in the both meta-analyses 
with COGA excluded (META NO COGA h2SNP = 0.0565; SE = 0.0039; p = 1.46e-47) and with FT12 excluded 
(META NO FT12 h2SNP = 0.058; SE = 0.0039; p = 5.02e-50). We see modest inflation in the test statistics (META 
NO COGA Mean χ2 = 1.1656; META NO FT12 Mean χ2 = 1.174). This genomic inflation appears to be the result of 
polygenic signal rather than population stratification, as the LDSC intercept is near one for each meta-analysis 
(META NO COGA Intercept = 1.0105, SE = 0.0065; META NO FT12 Intercept = 1.0108, SE = 0.0064). These 
GWAS meta-analysis results have a very high genetic correlation (rg = 0.9783, SE = 0.0017) 
 
 
Table S1: LDSC Estimates for GWAS included in Meta-Analysis 
  h2 rg (SE) 
 GWAS h2SNP SE p 1 2 3 
1 UKB AUDIT-P 0.0573 0.0050 2.15e-05 - - - 
2 PGC (no COGA) 0.0888 0.0209 7.17e-08 0.5869 (0.1229)  - - 







Table S2: Top SNPs from Meta-Analysis of PGC and UKB  
    NO COGA META NO FT12 META 
CHR POS RSID Nearest Gene Z P MAF Z P MAF 
4 100239319 rs1229984 ADH1B -6.77 1.26E-11 0.03 -7.13 9.78E-13 0.03 
4 100244221 rs3811802 ADH1B -8.02 1.02E-15 0.47 -8.13 4.18E-16 0.47 
4 100252560 rs3114045 ADH1C - - - -5.61 2.08E-08 0.13 
4 100262242 rs141973904 ADH1C -5.55 2.87E-08 0.02 -6.40 1.52E-10 0.02 
4 100282103 rs4699743 ADH1C -5.97 2.30E-09 0.08 -6.33 2.44E-10 0.08 
4 103385336 rs531685993 AF213884.1 5.75 8.89E-09 0.09 - - - 
4 99713350 rs144198753 BTF3P13 -9.73 2.33E-22 0.01 -9.73 2.33E-22 0.01 
4 39411407 rs62310819 KLB -5.47 4.50E-08 0.20 -5.52 3.38E-08 0.20 
4 39413780 rs28712821 KLB 6.59 4.27E-11 0.39 - - - 
4 39414993 rs11940694 KLB - - - -6.67 2.62E-11 0.39 
4 99941138 rs146788033 METAP1 9.57 1.03E-21 0.02 9.71 2.77E-22 0.02 
4 39393801 rs6842066 RNU6-887P 6.00 2.01E-09 0.42 - - - 
4 39400998 rs13110790 RNU6-887P - - - 6.74 1.58E-11 0.42 
4 99630017 rs193099203 
RP11-
1299A16.1 -8.08 6.61E-16 0.01 -8.08 6.61E-16 0.01 
4 100186847 rs138423208 
RP11-
696N14.1 6.70 2.16E-11 0.05 6.60 4.20E-11 0.05 
4 103198082 rs13135092 SLC39A8 7.77 7.69E-15 0.09 7.92 2.39E-15 0.09 












Figure S1: QQ Plots for UK Biobank and PGC GWAS Meta Analyses 






Figure S2: Manhattan Plots for UK Biobank and PGC GWAS Meta Analyses 
Manhattan plots of –log10 p-values for SNPS in meta-analysis with COGA (top) and FT12 (bottom) excluded.  
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3. Calculating AUC for PRS  
 
 While there is increasing focus on using the extreme ends of the polygenic risk continuum to as a potential 
way of identifying those at increased risk 17, 18, this method is not without its limitations. One critique, is that even 
though individuals at the top of the distribution may demonstrate increased risk, this does not mean that PRS are 
useful for clinical purposes 19. We therefore calculated the area under the curve (AUC) from receiver operating 
characteristic (ROC) curves as an additional check on any potential utility of PRS for alcohol use disorders (AUD) 
20 using the pROC package in R21. ROC curves compare the sensitivity (true positive rate) and specificity (false 
positive rate) to identify an indicators ability to correctly classify an individual as having a disease/disorder or not. 
 Where the true positive rate (sensitivity) equals: 
 
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑅𝑎𝑡𝑒 =  
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑇𝑟𝑢𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 +  𝐹𝑎𝑙𝑠𝑒 𝑁𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
 
 
The false positive rate is therefore equal to: 
 
𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑅𝑎𝑡𝑒 =  
𝐹𝑎𝑙𝑠𝑒 𝑃𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠













Figure S3: Prevalence of AUD Across PRS Continuum 
Mean Prevalence of mild, moderate, and severe AUD in COGA GSCAN DPW, PROB ALC, and RISK PC PRSs. Red 
vertical line denotes 95% point in the continuum. Fitted lines include least squares line and a loess curve. 
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5. Restricting Age Range in COGA 
 
 Because the age ranges in COGA and FT12 varied so widely, we ran a series of sensitivity analyses to 
ensure that differences across samples were not the result of age differences. We reran all of the analyses in the 
manuscript restricting the COGA sample to those aged 18 to 30 years old. The results of predictive power, increase 
in prevalence of AUD across septiles, and joint influence of PRS are not substantively different from the results in 




Table S3: Odds Ratios for Those at Extreme End of the PRS Continuum in COGA (ages 18-30) 
 
Sample Phenotype Split  N Cases OR 95 % CI Low 95 % CI High 
 Mild AUD 80% 355 1.81 1.45 2.26 
COGA Mild AUD 90% 172 1.55 1.15 2.08 
 Mild AUD 95% 86 1.44 0.96 2.15 
       
 Moderate AUD 80% 212 1.67 1.33 2.10 
COGA Moderate AUD 90% 107 1.61 1.19 2.19 
 Moderate AUD 95% 54 1.47 0.97 2.22 
       
 Severe AUD 80% 122 1.57 1.20 2.05 
COGA Severe AUD 90% 64 1.60 1.13 2.27 
 Severe AUD 95% 30 1.25 0.77 2.02 
       
All models control for sex, age at last interview, and first 10 principal components. Models for COGA also included data collection site and 
genotyping array. N Cases = number of individuals who meet criteria for a given level of AUD and are in the top portion of the split. 




Figure S4: Parameter Estimates for PRS in Independent and Joint Models 
Parameter estimates from linear mixed models for AUD symptoms regressed on GSCAN DPW, PROB ALC, and 
RISK PC PRS in COGA (age restricted). Independent = model with only corresponding PRS. Conditional = model 
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